Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis

Yaseen M. Arabi(Ministry of National Defense), Fahad Al-Hameed(Ministry of National Defense), Karen E. A. Burns(St. Michael's Hospital), Sangeeta Mehta(Ministry of National Defense), Sami Alsolamy(Ministry of National Defense), Mohammed Alshahrani(Ministry of National Defense), Yasser Mandourah(Ministry of National Defense), Ghaleb A. Almekhlafi(Riyadh Armed Forces Hospital), Mohammed Almaani(Ministry of National Defense), Ali Al Bshabshe(Ministry of National Defense), Simon Finfer(Ministry of National Defense), Zia Arshad(Ministry of National Defense), Imran Khalid(Ministry of National Defense), Yatin Mehta(Ministry of National Defense), Atul Gaur(Ministry of National Defense), Hassan Hawa(Ministry of National Defense), Hergen Buscher(St. Vincent's Birmingham), Hani Lababidi(Ministry of National Defense), Abdulsalam Al Aithan(Ministry of National Defense), Sheryl Ann Abdukahil(Ministry of National Defense), Jesna Jose(Ministry of National Defense), Lara Afesh(Ministry of National Defense), Abdulaziz Al‐Dawood(Ministry of National Defense)
New England Journal of Medicine
February 18, 2019
Cited by 217Open Access
Full Text

Abstract

BACKGROUND: Whether adjunctive intermittent pneumatic compression in critically ill patients receiving pharmacologic thromboprophylaxis would result in a lower incidence of deep-vein thrombosis than pharmacologic thromboprophylaxis alone is uncertain. METHODS: We randomly assigned patients who were considered adults according to the local standards at the participating sites (≥14, ≥16, or ≥18 years of age) within 48 hours after admission to an intensive care unit (ICU) to receive either intermittent pneumatic compression for at least 18 hours each day in addition to pharmacologic thromboprophylaxis with unfractionated or low-molecular-weight heparin (pneumatic compression group) or pharmacologic thromboprophylaxis alone (control group). The primary outcome was incident (i.e., new) proximal lower-limb deep-vein thrombosis, as detected on twice-weekly lower-limb ultrasonography after the third calendar day since randomization until ICU discharge, death, attainment of full mobility, or trial day 28, whichever occurred first. RESULTS: A total of 2003 patients underwent randomization - 991 were assigned to the pneumatic compression group and 1012 to the control group. Intermittent pneumatic compression was applied for a median of 22 hours (interquartile range, 21 to 23) daily for a median of 7 days (interquartile range, 4 to 13). The primary outcome occurred in 37 of 957 patients (3.9%) in the pneumatic compression group and in 41 of 985 patients (4.2%) in the control group (relative risk, 0.93; 95% confidence interval [CI], 0.60 to 1.44; P = 0.74). Venous thromboembolism (pulmonary embolism or any lower-limb deep-vein thrombosis) occurred in 103 of 991 patients (10.4%) in the pneumatic compression group and in 95 of 1012 patients (9.4%) in the control group (relative risk, 1.11; 95% CI, 0.85 to 1.44), and death from any cause at 90 days occurred in 258 of 990 patients (26.1%) and 270 of 1011 patients (26.7%), respectively (relative risk, 0.98; 95% CI, 0.84 to 1.13). CONCLUSIONS: Among critically ill patients who were receiving pharmacologic thromboprophylaxis, adjunctive intermittent pneumatic compression did not result in a significantly lower incidence of proximal lower-limb deep-vein thrombosis than pharmacologic thromboprophylaxis alone. (Funded by King Abdulaziz City for Science and Technology and King Abdullah International Medical Research Center; PREVENT ClinicalTrials.gov number, NCT02040103; Current Controlled Trials number, ISRCTN44653506.).


Related Papers

No related papers found

Powered by citation graph analysis